Panel Agrees: 2 LDL Receptor Patents Are Not Sufficiently Enabled

Mealey's (February 16, 2021, 1:54 PM EST) -- WASHINGTON, D.C. — In a blow to Amgen Inc. and two subsidiaries, the Federal Circuit U.S. Court of Appeals on Feb. 11 upheld findings by a federal judge in Delaware that...
To view the full article, register now.